▶ SERMORELIN · SUBTOPIC · SAFETY PROFILE

SERMORELIN Safety Profile

For Laboratory Research Use Only. This page summarises observed adverse events and regulatory status reported in the peer- reviewed literature. It is not medical advice and does not recommend any human use of SERMORELIN.

OBSERVED ADVERSE EVENTS IN LITERATURE

The following adverse events have been observed in trials or animal studies of SERMORELIN. Severity, frequency, and attribution depend on the source publication.

Injection-site reactions
Flushing
Headache
Mild taste alteration

DRUG INTERACTIONS

The following interactions are reported in or theorised from the published mechanism for SERMORELIN.

Concurrent glucocorticoids may blunt GH response
Levothyroxine (may need dose adjustment)

CONTRAINDICATIONS REPORTED IN LITERATURE

Contraindications recorded for SERMORELIN in the published record:

Active malignancy
Pituitary surgery (pre-existing GH excess)
Hypersensitivity

FDA REGULATORY STATUS

Previously FDA-approved as Geref (1997) for pediatric GH deficiency. Voluntarily withdrawn from US market for commercial reasons. Research-use only as of 2026.

WADA REGULATORY STATUS

Prohibited at all times under WADA Section S2 (GHRH analog sub-category).

SAFETY Q+A FROM LITERATURE

▶ Is sermorelin FDA-approved?

Sermorelin was previously FDA-approved as Geref (1997) for pediatric growth hormone deficiency. It was voluntarily withdrawn from the US market for commercial reasons (not safety) and is research-use only as of 2026.

▶ Is sermorelin WADA-prohibited?

Yes. Sermorelin is prohibited at all times under WADA Section S2 in the GHRH-analog sub-category.

▶ Why was Geref withdrawn?

The withdrawal was for commercial reasons rather than safety or efficacy. The pediatric GHD market shifted to recombinant human GH (somatropin), which provides direct GH replacement rather than depending on a functional pituitary.

CITED LITERATURE

The safety statements above are drawn from the following peer-reviewed sources. Refer to the originals for adverse- event tables, attribution, and full context.

Walker RF. Sermorelin: A better approach to management of adult-onset growth hormone insufficiency?. Clin Interv Aging 2006. PMID 18046871. link
FDA Center for Drug Evaluation and Research. FDA approval of sermorelin (Geref) for pediatric growth hormone deficiency. FDA approval letter 1997. link

◀ SERMORELIN OVERVIEW MECHANISM ▶DOSING LITERATURE ▶

▶ LAST UPDATED · 2026-05-25